Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 26 citing articles:

Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Shujing Wang, Jingrui Wang, Zhiqiang Chen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 158
Myeloid-derived suppressor cells in cancer and cancer therapy
Samantha Lasser, Feyza Gül Özbay Kurt, Ihor Arkhypov, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 147-164
Closed Access | Times Cited: 146
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Qian Hu, Qihui Bian, Dingchao Rong, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 142
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
María Florencia Soler, Andrea Abaurrea, Peio Azcoaga, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 11, pp. e007530-e007530
Open Access | Times Cited: 68
Neutrophils in Cancer immunotherapy: friends or foes?
Xueqin Huang, Eugenie Nepovimová, Vojtěch Adam, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 45
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Greta Pessino, Claudia Scotti, Maristella Maggi
Cancers (2024) Vol. 16, Iss. 5, pp. 901-901
Open Access | Times Cited: 20
Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation
Beiyuan Zhang, Chao Qin, Xue Wang, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 221-235
Closed Access | Times Cited: 1
Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation
Weiyuan Wang, Melanie Cristina Lopez McDonald, Rajashree Hariprasad, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1387-1387
Open Access | Times Cited: 7
Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Dandan Shi, Jiejing Tao, Shuli Man, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189207-189207
Closed Access | Times Cited: 7
The Talented LncRNAs: Meshing into Transcriptional Regulatory Networks in Cancer
Dana Segal, Josée Dostie
Cancers (2023) Vol. 15, Iss. 13, pp. 3433-3433
Open Access | Times Cited: 16
Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress
Bogdan Dume, Emilia Licărete, Manuela Banciu
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102256-102256
Open Access | Times Cited: 6
Cytokines in cancer
Courtney T.S. Kureshi, Stephanie K. Dougan
Cancer Cell (2024) Vol. 43, Iss. 1, pp. 15-35
Closed Access | Times Cited: 6
Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
Andrew Meci, Neerav Goyal, Guy Slonimsky
Cancers (2024) Vol. 16, Iss. 4, pp. 703-703
Open Access | Times Cited: 4
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes
Zoe King, Sudhamsh Reddy Desai, David A. Frank, et al.
Neoplasia (2025) Vol. 61, pp. 101137-101137
Closed Access
Harnessing myeloid cells in cancer
Suyeon Park, Ekaterina Pylaeva, Vikas Bhuria, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Design and Preliminary Screen of Antisense Oligonucleotides
Nofar Mor, Sharon Avkin-Nachum, Dan Dominissini
Methods in molecular biology (2025), pp. 51-61
Closed Access
The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses
Giuseppe Ciccone, Maria L. Ibba, Gabriele Coppola, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6121-6121
Open Access | Times Cited: 7
Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers Matter
Sara Molenda, Agata Sikorska, Anna Florczak, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5647-5647
Open Access | Times Cited: 7
Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer
Connor H. O’Meara, Zuhayr Jafri, Levon M. Khachigian
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11695-11695
Open Access | Times Cited: 6
RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials
Tiffaney Hsia, Yunching Chen
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 197, pp. 114234-114234
Closed Access | Times Cited: 2
BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment
Maria Cristina Gagliardi, Rhonda Kean, Bingbing Dai, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1901-1901
Open Access | Times Cited: 1
STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review)
Liliana Guadalupe Cortes-Ballinas, Tania V. López-Pérez, Leticia Rocha‐Zavaleta
Biomedical Reports (2024) Vol. 21, Iss. 6
Open Access | Times Cited: 1
Epithelial Mesenchymal Transition: The Ultimate Driver of Cancer on Difficult Paths
Devavrat Tripathi, Pramod Gupta, Savita Kulkarni
Journal of Cancer Immunology (2023) Vol. 5, Iss. 1, pp. 40-60
Open Access | Times Cited: 1
Advances in RNA therapeutics for modulation of ‘undruggable’ targets
Emily Martinsen, Tasmia Jinnurine, Saranya Subramani, et al.
Progress in molecular biology and translational science (2024), pp. 249-294
Closed Access
Novel immunotherapy combinations in neoadjuvant non-small cell lung cancer (NSCLC): a better chance at cure?
Alexander I. Salter, Millie Das
Translational Lung Cancer Research (2024) Vol. 13, Iss. 3, pp. 673-677
Open Access
Page 1 - Next Page

Scroll to top